A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer
What is the purpose of this trial?
The primary objective is safety and tolerability of BMS-936558 in combination with chemotherapy. The primary objective will be measured by: 1) Frequency of adverse events occurring up to 30 days after the last dose of study drug (or longer for drug-related AEs that have not resolved, stabilized, retuned to baseline or been deemed irreversible by 30 days after the last dose) 2) Frequency of serious adverse events occurring up to 90 days after the last dose of study drug (or longer for drug-related SAEs that have notresolved, stabilized, retuned to baseline or been deemed irreversible by 90 days after the last dose) 3) frequency of clinical laboratory test by worst toxicity grade (as assessed at screening, Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2+, and end of treatment).
- Bristol-Myers Squibb Company
- Last Updated:
- Study HIC#: